{
    "id": 23009,
    "fullName": "FGFR2 - SHTN1",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2-SHTN1 (also referred to as FGFR2-KIAA1598) results from the fusion of FGFR2 and SHTN1, which has been demonstrated to result in increased phosphorylation of recombinant protein S6, Akt, and mTOR in cultured cells (PMID: 31911531), and therefore, is predicted to lead to a gain of protein function. FGFR2-SHTN1 has been identified in cholangiocarinoma (PMID: 25536104, PMID: 31911531) and non-small cell lung cancer (PMID: 30267839).",
            "references": [
                {
                    "id": 5800,
                    "pubMedId": 25536104,
                    "title": "Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25536104"
                },
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 15167,
                    "pubMedId": 30267839,
                    "title": "Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30267839"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "FGFR2 - SHTN1",
    "createDate": "06/06/2016",
    "updateDate": "02/03/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 57698,
                "geneSymbol": "SHTN1",
                "terms": [
                    "SHTN1",
                    "KIAA1598",
                    "shootin-1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 19831,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FGFR2-SHTN1 were sensitive to treatment with Iclusig (ponatinib), demonstrating decreased cell viability in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 23681,
                "profileName": "FGFR2 - SHTN1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19827,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FGFR2-SHTN1 were sensitive to treatment with Balversa (erdafitinib), demonstrating decreased cell viability in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 23681,
                "profileName": "FGFR2 - SHTN1"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19824,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FGFR2-SHTN1 were sensitive to treatment with AZD4547, demonstrating decreased cell viability in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 23681,
                "profileName": "FGFR2 - SHTN1"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19829,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing FGFR2-SHTN1 were sensitive to treatment with Futibatinib (TAS-120), demonstrating decreased cell viability in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 23681,
                "profileName": "FGFR2 - SHTN1"
            },
            "therapy": {
                "id": 1053,
                "therapyName": "Futibatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19826,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing FGFR2-SHTN1 were sensitive to treatment with Balversa (erdafitinib), demonstrating decreased cell viability in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 23681,
                "profileName": "FGFR2 - SHTN1"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19838,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FGFR2-SHTN1 demonstrated resistance to treatment with Dovitinib (TKI258) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 23681,
                "profileName": "FGFR2 - SHTN1"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19839,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing FGFR2-SHTN1 demonstrated resistance to treatment with Dovitinib (TKI258) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 23681,
                "profileName": "FGFR2 - SHTN1"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19830,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing FGFR2-SHTN1 were sensitive to treatment with Iclusig (ponatinib), demonstrating decreased cell viability in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 23681,
                "profileName": "FGFR2 - SHTN1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19825,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing FGFR2-SHTN1 were sensitive to treatment with AZD4547, demonstrating decreased cell viability in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 23681,
                "profileName": "FGFR2 - SHTN1"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19813,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with cholangiocarcinoma harboring FGFR2-SHTN1 experienced a partial response according to RECIST criteria after four months of treatment with Infigratinib (BGJ398) (PMID: 31911531).",
            "molecularProfile": {
                "id": 23681,
                "profileName": "FGFR2 - SHTN1"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19828,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FGFR2-SHTN1 were sensitive to treatment with Futibatinib (TAS-120), demonstrating decreased cell viability in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 23681,
                "profileName": "FGFR2 - SHTN1"
            },
            "therapy": {
                "id": 1053,
                "therapyName": "Futibatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19854,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Iclusig (ponatinib) and Sapanisertib (MLN0128) resulted in synergistic effects in transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 9234,
                "therapyName": "Ponatinib + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19833,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 E565A demonstrated resistance to treatment with AZD4547 in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19835,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A demonstrated resistance to treatment with Balversa (erdafitinib) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19837,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 E565A demonstrated resistance to treatment with Futibatinib (TAS-120) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 1053,
                "therapyName": "Futibatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19853,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A to treatment with Balversa (erdafitinib), demonstrating synergistic effects (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 9233,
                "therapyName": "Erdafitinib + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19842,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A were sensitive to treatment with Iclusig (ponatinib) in culture, demonstrating reduced cell viability (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19817,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 E565A demonstrated resistance to treatment with Infigratinib (BGJ398) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19832,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A demonstrated resistance to treatment with AZD4547 in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19836,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A demonstrated resistance to treatment with Futibatinib (TAS-120) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 1053,
                "therapyName": "Futibatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19841,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A demonstrated resistance to treatment with Dovitinib (TKI258) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19850,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 E565A were sensitive to treatment with Iclusig (ponatinib) in culture, demonstrating reduced cell viability (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 E565A demonstrated resistance to treatment with Balversa (erdafitinib) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19840,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 E565A demonstrated resistance to treatment with Dovitinib (TKI258) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19818,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A demonstrated resistance to treatment with Infigratinib (BGJ398) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19852,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A to treatment with AZD4547, demonstrating synergistic effects (PMID: 31911531).",
            "molecularProfile": {
                "id": 34526,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A"
            },
            "therapy": {
                "id": 9232,
                "therapyName": "AZD4547 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19816,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with cholangiocarcinoma harboring FGFR2-SHTN1 initially responded to treatment with Infigratinib (BGJ398), but progressed after eight months and via repeat tissue biopsy was found to have acquired FGFR2 E565A, and via circulating tumor DNA testing, FGFR2 L617M (PMID: 31911531).",
            "molecularProfile": {
                "id": 34542,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A FGFR2 L617M"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19851,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A to treatment with Infigratinib (BGJ398), demonstrating synergistic effects (PMID: 31911531).",
            "molecularProfile": {
                "id": 34542,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A FGFR2 L617M"
            },
            "therapy": {
                "id": 9231,
                "therapyName": "BGJ398 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19848,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M were sensitive to treatment with Iclusig (ponatinib) in culture, demonstrating reduced cell viability (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19820,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Infigratinib (BGJ398) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19819,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Infigratinib (BGJ398) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19849,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 E565A were sensitive to treatment with Iclusig (ponatinib) in culture, demonstrating reduced cell viability (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19858,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M to treatment with Infigratinib (BGJ398), demonstrating synergistic effects (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 9231,
                "therapyName": "BGJ398 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Balversa (erdafitinib) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19843,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with AZD4547 in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M to treatment with AZD4547, demonstrating synergistic effects (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 9232,
                "therapyName": "AZD4547 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19856,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M to treatment with Balversa (erdafitinib), demonstrating synergistic effects (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 9233,
                "therapyName": "Erdafitinib + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19844,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with AZD4547 in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19847,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Futibatinib (TAS-120) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 1053,
                "therapyName": "Futibatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19855,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Iclusig (ponatinib) and Sapanisertib (MLN0128) resulted in synergistic effects in transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 9234,
                "therapyName": "Ponatinib + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19845,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Balversa (erdafitinib) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23681,
            "profileName": "FGFR2 - SHTN1",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34526,
            "profileName": "FGFR2 - SHTN1 FGFR2 E565A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34542,
            "profileName": "FGFR2 - SHTN1 FGFR2 E565A FGFR2 L617M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34543,
            "profileName": "FGFR2 - SHTN1 FGFR2 L617M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}